Twist Bioscience Corporation

NasdaqGS:TWST Stock Report

Mkt Cap: US$1.6b

We’ve recently updated our valuation analysis.

Twist Bioscience Valuation

Is TWST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TWST?

Other financial metrics that can be useful for relative valuation.

TWST key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue6.1x
Enterprise Value/EBITDA-5.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does TWST's PS Ratio compare to its peers?

The above table shows the PS ratio for TWST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average11.9x
XNCR Xencor
6.9x19.3%US$2.0b
BBIO BridgeBio Pharma
16.5x50.3%US$1.5b
VCYT Veracyte
6.6x13.6%US$1.9b
MORF Morphic Holding
17.5x27.3%US$1.3b
TWST Twist Bioscience
8.1x24.1%US$1.6b

Price-To-Sales vs Peers: TWST is good value based on its Price-To-Sales Ratio (8.1x) compared to the peer average (11.9x).


Price to Earnings Ratio vs Industry

How does TWST's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.2%
n/an/an/a

Price-To-Sales vs Industry: TWST is good value based on its Price-To-Sales Ratio (8.1x) compared to the US Biotechs industry average (12.9x)


Price to Sales Ratio vs Fair Ratio

What is TWST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TWST PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.1x
Fair PS Ratio5.4x

Price-To-Sales vs Fair Ratio: TWST is expensive based on its Price-To-Sales Ratio (8.1x) compared to the estimated Fair Price-To-Sales Ratio (5.4x).


Share Price vs Fair Value

What is the Fair Price of TWST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TWST's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TWST's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TWST forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$29.08
US$35.13
+20.8%
20.0%US$50.00US$24.00n/a8
Jan ’24US$23.81
US$35.14
+47.6%
24.0%US$50.00US$24.00n/a7
Dec ’23US$27.86
US$34.67
+24.4%
26.0%US$50.00US$24.00n/a6
Nov ’23US$33.77
US$46.00
+36.2%
16.4%US$56.00US$35.00n/a6
Oct ’23US$35.24
US$50.00
+41.9%
16.8%US$60.00US$35.00n/a6
Sep ’23US$40.46
US$50.00
+23.6%
16.8%US$60.00US$35.00n/a6
Aug ’23US$44.61
US$41.83
-6.2%
19.8%US$55.00US$30.00n/a6
Jul ’23US$37.08
US$40.50
+9.2%
19.1%US$55.00US$30.00n/a6
Jun ’23US$30.92
US$40.50
+31.0%
19.1%US$55.00US$30.00n/a6
May ’23US$28.84
US$62.00
+115.0%
11.2%US$70.00US$52.00n/a6
Apr ’23US$52.91
US$75.00
+41.8%
18.5%US$105.00US$65.00n/a6
Mar ’23US$55.50
US$75.00
+35.1%
18.5%US$105.00US$65.00n/a6
Feb ’23US$62.35
US$109.67
+75.9%
13.1%US$130.00US$85.00US$29.086
Jan ’23US$77.39
US$111.83
+44.5%
9.9%US$130.00US$98.00US$23.816
Dec ’22US$87.06
US$111.83
+28.5%
9.9%US$130.00US$98.00US$27.866
Nov ’22US$126.88
US$118.33
-6.7%
11.4%US$140.00US$100.00US$33.776
Oct ’22US$105.50
US$119.33
+13.1%
10.9%US$140.00US$100.00US$35.246
Sep ’22US$117.04
US$121.00
+3.4%
13.1%US$150.00US$100.00US$40.466
Aug ’22US$123.05
US$123.33
+0.2%
14.6%US$150.00US$100.00US$44.616
Jul ’22US$131.48
US$123.33
-6.2%
13.8%US$150.00US$100.00US$37.086
Jun ’22US$105.88
US$126.00
+19.0%
13.8%US$150.00US$100.00US$30.925
May ’22US$134.19
US$146.00
+8.8%
21.9%US$200.00US$100.00US$28.845
Apr ’22US$122.20
US$153.75
+25.8%
24.5%US$200.00US$100.00US$52.914
Mar ’22US$144.95
US$153.75
+6.1%
24.5%US$200.00US$100.00US$55.504
Feb ’22US$180.27
US$116.25
-35.5%
14.7%US$140.00US$100.00US$62.354

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies